The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues including medicines regulation, UK and EU trading relationships, access to talent, and the future of UK science.
The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.
The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines.
Clinical trials are the cornerstone of the research and development process and it is through trials that pharmaceutical companies are able to demonstrate the safety and efficacy of new medicines.
Medicines and vaccines have helped deliver incredible improvements in patient health. This section looks at expenditure on R&D in the UK and around the world.
The UK is a world leader in medical research and innovation, built on the foundation of collaborations between industry and academia throughout Britain.
Discover events for both members and non-members as well as speaking engagements of senior ABPI leadership.
As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.
ABPI Member webinar
The chance to hear a monthly update on the work and arrangements on Brexit and the implications for our business.
Friday 07 December 201812:00 - 13:00
The webinar will be hosted by Elliot Dunster, Head of External Affairs who will be joined by colleagues on specific issues as they arise.
Please note, this webinar is for ABPI member company colleagues only. Please ensure you register with your company email address in order to gain access.